Table 4.

Associations between baseline factors and treatment switching–stratified by DMT.

Factor at treatment start	DMT
	IFNβ	Glatiramer Acetate	Natalizumab	Fingolimod	Dimethyl fumarate	Teriflunomide
	Adjusted HR (95% CI) p-value	Adjusted HR (95% CI) p-value	Adjusted HR (95% CI) p-value	Adjusted HR (95% CI) p-value	Adjusted HR (95% CI) p-value	Adjusted HR (95% CI) p-value
Age at treatment start (10 year units)	1.05 (1.02, 1.07) <0.001	0.96 (0.93, 0.99) 0.019	1.02 (0.99, 1.05) 0.061	1.02 (0.99, 1.06) 0.166	1.08 (1.02, 1.13) 0.003	1.21 (1.13, 1.30) <0.001
Female sex	1.17 (1.11, 1.24) <0.001	1.03 (0.96, 1.11) 0.351	1.03 (0.97, 1.11) 0.335	1.05 (0.97, 1.14) 0.212	1.11 (0.98, 1.25) 0.102	1.26 (1.04, 1.51) 0.015
EDSS	1.09 (1.08, 1.11) <0.001	1.12 (1.10, 1.14) <0.001	1.01 (1.00, 1.03) 0.079	0.99 (0.99, 1.01) 0.273	0.99 (0.95, 1.01) 0.130	0.98 (0.93, 1.02) 0.293
Calendar year	1.15 (1.14, 1.15) <0.001	1.14 (1.13, 1.15) <0.001	1.35 (1.33, 1.37) <0.001	1.06 (1.04, 1.08) <0.001	1.00 (0.94, 1.05) 0.878	1.03 (0.98, 1.09) 0.309